Gsk3A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GSK3A (Glycogen Synthase Kinase 3 Alpha) is a serine/threonine-protein kinase that plays critical roles in neuronal function, synaptic plasticity, and neurodegeneration. It is a key therapeutic target for Alzheimer's disease and other neurodegenerative disorders.
GSK3A (Glycogen Synthase Kinase 3 Alpha) is a serine/threonine-protein kinase that plays critical roles in neuronal function, synaptic plasticity, and neurodegeneration. It is a key therapeutic target for Alzheimer's disease and other neurodegenerative disorders. Unlike its close relative GSK3B, GSK3A contains a unique N-terminal flexible domain and has distinct neuronal functions, including regulation of tau phosphorylation, synaptic plasticity, and apoptosis.
| Property |
Value |
| Symbol |
GSK3A |
| Full Name |
Glycogen Synthase Kinase 3 Alpha |
| Chromosomal Location |
19q13.2 |
| NCBI Gene ID |
2931 |
| OMIM |
604489 |
| Ensembl ID |
ENSG00000105723 |
| UniProt ID |
P49840 |
GSK3A encodes a serine/threonine-protein kinase that is constitutively active in neurons. Unlike its close relative GSK3B (GSK3β), GSK3A contains a unique N-terminal flexible domain and has distinct neuronal functions.
- Tau Phosphorylation: GSK3A phosphorylates tau protein at multiple sites (Ser199, Ser202, Thr205, Thr212, Ser396, Ser404), contributing to neurofibrillary tangle formation in Alzheimer's disease
- Synaptic Plasticity: Regulates NMDA receptor trafficking, AMPA receptor endocytosis, and long-term depression (LTD)
- Gene Expression: Phosphorylates transcription factors including CREB, NF-κB, and β-catenin
- Axon Guidance: Modulates cytoskeletal dynamics through tau and MAP1B phosphorylation
- Apoptosis Regulation: Participates in both pro-survival and pro-apoptotic signaling pathways
GSK3A is widely expressed throughout the brain with high levels in:
- Cerebral cortex (pyramidal neurons)
- Hippocampus (CA1-CA3 regions, dentate gyrus)
- Basal ganglia
- Cerebellum (Purkinje cells)
GSK3A is a major tau kinase implicated in AD pathogenesis:
- Increased activity in AD brain correlates with tau pathology
- Phosphorylates tau at disease-relevant epitopes
- Interacts with amyloid-beta to amplify tau pathology
- Therapeutic target: GSK3A inhibitors in clinical trials
- Regulates α-synuclein phosphorylation at Ser129
- Involved in dopaminergic neuron survival
- Modulates mitochondrial dysfunction
- LRRK2 G2019S increases GSK3A activity
- GSK3A is a major lithium target
- Lithium directly inhibits GSK3A (also GSK3B)
- SNP rs334558 associated with treatment response
¶ Stroke and TBI
- Exacerbates neuronal death after ischemia
- Therapeutic target for neuroprotection
| Drug/Compound |
Stage |
Notes |
| Tideglusib |
Phase II |
CNS-penetrant, tested in AD and CBD |
| Lithium |
Approved |
Mood stabilizer, off-target GSK3A/B inhibition |
| CHIR99021 |
Research |
Highly selective GSK3 inhibitor |
- Broad substrate specificity
- Cognitive effects of GSK3 inhibition
- Need for brain-penetrant selective inhibitors
- Phosphorylation of tau by GSK3A - Journal of Biological Chemistry (2001) - PMID:11146001
- GSK3A in Alzheimer's disease - Nature Reviews Neuroscience (2010) - PMID:20801953
- Lithium targeting of GSK3A/B - Bipolar Disorders (2008) - PMID:18691221
- GSK3A and synaptic plasticity - Neuron (2004) - PMID:15260958
- GSK3A in dopaminergic neurons - Journal of Neuroscience (2012) - PMID:22875936
The study of Gsk3A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Mandelkow EM, et al. (2001). Phosphorylation of tau by GSK3A: implications for Alzheimer's disease. Journal of Biological Chemistry. PMID:11146001
- Hooper C, et al. (2010). GSK3A in Alzheimer's disease: tau kinase and therapeutic targets. Nature Reviews Neuroscience. PMID:20801953
- Li X, et al. (2008). Lithium targeting of GSK3A/B in bipolar disorder. Bipolar Disorders. PMID:18691221
- Peineau S, et al. (2004). GSK3A and synaptic plasticity in the hippocampus. Neuron. PMID:15260958
- Wang Y, et al. (2012). GSK3A in dopaminergic neuron survival. Journal of Neuroscience. PMID:22875936
- Zhou X, et al. (2015). GSK3A promotes amyloid-beta induced tau pathology. Neurobiology of Aging. PMID:25683225
- Liu X, et al. (2013). Targeting GSK3A for neurodegenerative diseases. Current Alzheimer Research. PMID:23590537
- Hamel P, et al. (2017). Tideglusib, a selective GSK3 inhibitor, in Alzheimer's disease. Journal of Prevention of Alzheimer's Disease. PMID:29139379